Company Overview of Q-Biologicals NV
Q-Biologicals NV manufactures biological substances with the help of living, biological processes. The company engages in the production and purification of proteins. Q-Biologicals NV was founded in 2011 and is based in Gent, Belgium. As of January 25, 2016, Q-Biologicals NV operates as a subsidiary of Amatsigroup.
Founded in 2011
Key Executives for Q-Biologicals NV
Compensation as of Fiscal Year 2016.
Q-Biologicals NV Key Developments
Propanc Health Group Corporation Enters into Contract Manufacturing Agreement with AmatsiQBiologicals
Aug 23 16
Propanc Health Group Corporation announced it has executed a contract manufacturing agreement with AmatsiQBiologicals. The agreement covers the development and GMP (Good Manufacturing Practice) production of certain enzymes for development purposes, including but not limited to first-in-man studies for the Company's lead product, PRP. PRP is the Company's novel, patented, formulation consisting of two proenzymes mixed in a synergistic ratio to target cancer stem cells in solid tumors. The GMP manufacture of PRP as an injectable drug product requires specialized and detailed activities to be carried out in order to meet the high quality and safety standards for future human use. It is a significant undertaking by the Company, as it demonstrates the Company's commitment to initiating first-in-man studies in 2017. Pursuant to the Manufacturing Services Agreement, Q-Biologicals will produce certain drug substances and product containing certain enzymes at its facility in Belgium. The company will use these substances and products for development purposes, including but not limited to clinical trials. The MSA contemplates payment to Q-Biologicals pursuant to a pre-determined fee schedule based on the completion of certain milestones that depend on the company's manufacturing requirements and final batch yield. The Company anticipates that its payments to Q-Biologicals under the MSA will range between $2.5 million and $5.0 million over five years, with the majority of the expenditures occurring during the first two years of the MSA when the finished drug product is manufactured and released for clinical trials, including a pre-payment to Q-Biologicals of approximately $144,000.
Q-Biologicals NV Presents at BIO-Europe 2015, Nov-02-2015
Oct 9 15
Q-Biologicals NV Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 25, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries